515 related articles for article (PubMed ID: 26187456)
1. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.
Bisaga A; Sullivan MA; Glass A; Mishlen K; Pavlicova M; Haney M; Raby WN; Levin FR; Carpenter KM; Mariani JJ; Nunes EV
Drug Alcohol Depend; 2015 Sep; 154():38-45. PubMed ID: 26187456
[TBL] [Abstract][Full Text] [Related]
2. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
[TBL] [Abstract][Full Text] [Related]
3. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
[TBL] [Abstract][Full Text] [Related]
4. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence.
Bisaga A; Sullivan MA; Glass A; Mishlen K; Carpenter KM; Mariani JJ; Levin FR; Nunes EV
J Subst Abuse Treat; 2014; 46(5):546-52. PubMed ID: 24560438
[TBL] [Abstract][Full Text] [Related]
5. Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
Levin FR; Mariani JJ; Pavlicova M; Choi CJ; Basaraba C; Mahony AL; Brooks DJ; Naqvi N; Bisaga A
Drug Alcohol Depend; 2021 Feb; 219():108482. PubMed ID: 33418204
[TBL] [Abstract][Full Text] [Related]
6. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
Krupitsky E; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Silverman BL
Lancet; 2011 Apr; 377(9776):1506-13. PubMed ID: 21529928
[TBL] [Abstract][Full Text] [Related]
7. Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-Wedge Cluster Randomized Clinical Trial.
Shulman M; Greiner MG; Tafessu HM; Opara O; Ohrtman K; Potter K; Hefner K; Jelstrom E; Rosenthal RN; Wenzel K; Fishman M; Rotrosen J; Ghitza UE; Nunes EV; Bisaga A
JAMA Netw Open; 2024 May; 7(5):e249744. PubMed ID: 38717773
[TBL] [Abstract][Full Text] [Related]
8. Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans.
Lofwall MR; Babalonis S; Nuzzo PA; Elayi SC; Walsh SL
Drug Alcohol Depend; 2016 Jul; 164():143-150. PubMed ID: 27234658
[TBL] [Abstract][Full Text] [Related]
9. A week-long outpatient induction onto XR-naltrexone in patients with opioid use disorder.
Sibai M; Mishlen K; Nunes EV; Levin FR; Mariani JJ; Bisaga A
Am J Drug Alcohol Abuse; 2020 May; 46(3):289-296. PubMed ID: 31860366
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
11. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.
Sullivan MA; Bisaga A; Glass A; Mishlen K; Pavlicova M; Carpenter KM; Mariani JJ; Levin FR; Nunes EV
Drug Alcohol Depend; 2015 Feb; 147():122-9. PubMed ID: 25555621
[TBL] [Abstract][Full Text] [Related]
12. Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.
Nunes EV; Bisaga A; Krupitsky E; Nangia N; Silverman BL; Akerman SC; Sullivan MA
Addiction; 2020 Feb; 115(2):239-246. PubMed ID: 31313402
[TBL] [Abstract][Full Text] [Related]
13. Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.
Shulman M; Hu MC; Sullivan MA; Akerman SC; Fratantonio J; Barbieri V; Nunes EV; Bisaga A
Drug Alcohol Depend; 2022 Apr; 233():109343. PubMed ID: 35131528
[TBL] [Abstract][Full Text] [Related]
14. Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder.
Shi Z; Wang AL; Jagannathan K; Fairchild VP; O'Brien CP; Childress AR; Langleben DD
J Psychiatry Neurosci; 2018 Jul; 43(4):254-261. PubMed ID: 29947607
[TBL] [Abstract][Full Text] [Related]
15. Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone: A Randomized Clinical Trial and Follow-up Study.
Latif ZE; Šaltyte Benth J; Solli KK; Opheim A; Kunoe N; Krajci P; Sharma-Haase K; Tanum L
JAMA Psychiatry; 2019 Feb; 76(2):127-134. PubMed ID: 30566177
[TBL] [Abstract][Full Text] [Related]
16. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients.
Syed YY; Keating GM
CNS Drugs; 2013 Oct; 27(10):851-61. PubMed ID: 24018540
[TBL] [Abstract][Full Text] [Related]
17. Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.
Sullivan M; Bisaga A; Pavlicova M; Choi CJ; Mishlen K; Carpenter KM; Levin FR; Dakwar E; Mariani JJ; Nunes EV
Am J Psychiatry; 2017 May; 174(5):459-467. PubMed ID: 28068780
[TBL] [Abstract][Full Text] [Related]
18. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community.
Di Paola A; Lincoln T; Skiest DJ; Desabrais M; Altice FL; Springer SA
Contemp Clin Trials; 2014 Nov; 39(2):256-68. PubMed ID: 25240704
[TBL] [Abstract][Full Text] [Related]
19. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.
Collins ED; Kleber HD; Whittington RA; Heitler NE
JAMA; 2005 Aug; 294(8):903-13. PubMed ID: 16118380
[TBL] [Abstract][Full Text] [Related]
20. [Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
Krupitskiĭ EM; Nunes EV; Ling W; Illeperuma A; Gastfriend DR; Blokhina EA; Silverman BL
Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(5 Pt 2):3-11. PubMed ID: 22951790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
